Diabetes, obesity & metabolism · 2025
Comparative efficacy and safety of Glucagon-like pepetide-1 receptor agonists with metformin in Asian versus non-Asian patients with type 2 diabetes: A systematic review and meta-analysis.
СтатьяМетаанализСистематический обзорСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Wenxuan, Huang Linyan, Wang Ruixue, Peng Peiyan, Song Aowen, Zeng Yi, Zhang Zhen
Аннотация
AIMS: In type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) in combination with metformin show better efficacy than metformin alone. Nevertheless, the reactions of different ethnic groups, especially Asian and non-Asian populations, are still controversial. To give clinical medication usage an evidence-based foundation, this meta-analysis examined GLP-1RAs' safety and efficacy when combined with metformin in the treatment of type 2 diabetes mellitus.
MATERIALS AND METHODS: Up to January 2025, systematic searches for randomised controlled trials were carried out in PubMed, Embase, the Cochrane Library, SinoMed and Wanfang comparing GLP-1RA/metformin combination versus metformin alone in type 2 diabetes, with subgroup analyses for Asian versus non-Asian cohorts. RevMan version 5.3 was used for analyses, and the Cochrane tools for risk of bias were used for quality assessment.
RESULTS: This meta-analysis comprised 11 papers in total (6 Asian trials: 750 people; 5 non-Asian trials: 1096 people). After treatment of GLP-1RAs combined with metformin, the Asian group showed greater improvement in glycosylated haemoglobin (HbA1c) (weighted mean differences [WMD], -1.09; 95% confidence intervals [CI], -1.48 to -0.71; subgroup heterogeneity: I2 = 77.7%, p < 0.05) and weight (WMD, -4.16; 95% CI -6.11 to -2.22; subgroup heterogeneity: I2 = 89.5%, p < 0.05) with a lower gastrointestinal (GI) events risk (relative risks, 0.76; 95% CI, 0.47 to 1.22; subgroup heterogeneity: I2 = 93.7%, p < 0.00001). There were no racial variations in fasting glucose levels (p = 0.78) or hypoglycaemia (p = 0.16).
CONCLUSIONS: This meta-analysis suggested potential ethnic variations in the treatment combining GLP-1RAs with metformin, with Asian populations achieving superior HbA1c reduction and weight loss alongside better GI tolerance.
MATERIALS AND METHODS: Up to January 2025, systematic searches for randomised controlled trials were carried out in PubMed, Embase, the Cochrane Library, SinoMed and Wanfang comparing GLP-1RA/metformin combination versus metformin alone in type 2 diabetes, with subgroup analyses for Asian versus non-Asian cohorts. RevMan version 5.3 was used for analyses, and the Cochrane tools for risk of bias were used for quality assessment.
RESULTS: This meta-analysis comprised 11 papers in total (6 Asian trials: 750 people; 5 non-Asian trials: 1096 people). After treatment of GLP-1RAs combined with metformin, the Asian group showed greater improvement in glycosylated haemoglobin (HbA1c) (weighted mean differences [WMD], -1.09; 95% confidence intervals [CI], -1.48 to -0.71; subgroup heterogeneity: I2 = 77.7%, p < 0.05) and weight (WMD, -4.16; 95% CI -6.11 to -2.22; subgroup heterogeneity: I2 = 89.5%, p < 0.05) with a lower gastrointestinal (GI) events risk (relative risks, 0.76; 95% CI, 0.47 to 1.22; subgroup heterogeneity: I2 = 93.7%, p < 0.00001). There were no racial variations in fasting glucose levels (p = 0.78) or hypoglycaemia (p = 0.16).
CONCLUSIONS: This meta-analysis suggested potential ethnic variations in the treatment combining GLP-1RAs with metformin, with Asian populations achieving superior HbA1c reduction and weight loss alongside better GI tolerance.